Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

Similar articles for PubMed (Select 21364065)

1.

Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.

Bolhaar MG, Karstaedt AS.

Int J STD AIDS. 2011 Jan;22(1):38-42. doi: 10.1258/ijsa.2010.010229.

PMID:
21364065
2.

Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.

McMahon DK, Zheng L, Hitti J, Chan ES, Halvas EK, Hong F, Kabanda J, Taulo F, Kumarasamy N, Bonhomme J, Wallis CL, Klingman KL, Hughes MD, Mellors JW.

Clin Infect Dis. 2013 Apr;56(7):1044-51. doi: 10.1093/cid/cis1219. Epub 2013 Jan 8.

3.

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.

McIntyre JA, Hopley M, Moodley D, Eklund M, Gray GE, Hall DB, Robinson P, Mayers D, Martinson NA.

PLoS Med. 2009 Oct;6(10):e1000172. doi: 10.1371/journal.pmed.1000172. Epub 2009 Oct 27.

4.

Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.

Kuhn L, Semrau K, Ramachandran S, Sinkala M, Scott N, Kasonde P, Mwiya M, Kankasa C, Decker D, Thea DM, Aldrovandi GM.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):132-6. doi: 10.1097/QAI.0b013e3181ab6d5e.

5.

Response to antiretroviral therapy after a single, peripartum dose of nevirapine.

Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, Essex M.

N Engl J Med. 2007 Jan 11;356(2):135-47.

6.

Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.

Wagner TA, Kress CM, Beck I, Techapornroong M, Wittayapraparat P, Tansuphasawasdikul S, Jourdain G, Ngo-Giang-Huong N, Lallemant M, Frenkel LM.

J Clin Microbiol. 2010 May;48(5):1555-61. doi: 10.1128/JCM.02062-09. Epub 2010 Feb 24.

7.

Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.

Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R.

Clin Infect Dis. 2011 Oct;53(7):716-24. doi: 10.1093/cid/cir447.

8.

Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.

Palmer S, Boltz VF, Chow JY, Martinson NA, McIntyre JA, Gray GE, Hopley MJ, Mayers D, Robinson P, Hall DB, Maldarelli F, Coffin JM, Mellors JW; 1100.1413 Trial Investigators.

Antivir Ther. 2012;17(2):327-36. doi: 10.3851/IMP1946. Epub 2011 Nov 3.

PMID:
22293443
9.

Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).

Onyango-Makumbi C, Omer SB, Mubiru M, Moulton LH, Nakabiito C, Musoke P, Mmiro F, Zwerski S, Wigzell H, Falksveden L, Wahren B, Antelman G, Fowler MG, Guay L, Jackson JB.

J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):399-407. doi: 10.1097/QAI.0b013e31822f8914.

10.

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.

11.

Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.

Walter J, Kuhn L, Kankasa C, Semrau K, Sinkala M, Thea DM, Aldrovandi GM.

BMC Infect Dis. 2008 Dec 30;8:172. doi: 10.1186/1471-2334-8-172.

12.

Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.

Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, Mahamat A, Martinez V, Pradier C, Rouveix E, Simon A, Costagliola D, Abgrall S; FHDH-ANRS CO4.

J Antimicrob Chemother. 2011 Aug;66(8):1869-77. doi: 10.1093/jac/dkr208. Epub 2011 Jun 1.

13.

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.

Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley RT, Hughes MD, Coffin JM, Mellors JW; OCTANE/A5208 Team.

J Infect Dis. 2014 Mar 1;209(5):703-10. doi: 10.1093/infdis/jit635. Epub 2014 Jan 16.

14.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

15.

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.

AIDS. 2006 Oct 24;20(16):2099-106.

PMID:
17053356
16.

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M; Perinatal HIV Prevention Trial Group.

N Engl J Med. 2004 Jul 15;351(3):229-40. Epub 2004 Jul 9.

17.

The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 2007 to May 2009.

Namukwaya Z, Mudiope P, Kekitiinwa A, Musoke P, Matovu J, Kayma S, Salmond W, Bitarakwate E, Mubiru M, Maganda A, Galla M, Byamugisha J, Fowler MG.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):69-75. doi: 10.1097/QAI.0b013e3181fdb4a8.

PMID:
21099692
18.

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.

Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A.

HIV Med. 2004 Mar;5(2):105-9.

PMID:
15012650
19.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
20.

Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.

Martinson NA, Morris L, Johnson J, Gray GE, Pillay V, Ledwaba J, Dhlamini P, Cohen S, Puren A, Steyn J, Heneine W, McIntyre JA.

AIDS. 2009 Apr 27;23(7):809-16. doi: 10.1097/QAD.0b013e328323ad49.

PMID:
19287298
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk